

ANTIBIOTIC RESISTANCE AND VIRULENCE PROPERTIES IN *ESCHERICHIA COLI* STRAINS FROM CASES OF URINARY TRACT INFECTIONSFelix Oluwasola. Olorunmola<sup>1\*</sup> Deboye Oriade Kolawole<sup>2</sup> and Adebayo Lamikanra<sup>3</sup><sup>1</sup>Drug Research and Production, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.\*E-mail: [folorunmola@gmail.com](mailto:folorunmola@gmail.com)<sup>2</sup>Department of Microbiology, Faculty of Science, Obafemi Awolowo University, Ile-Ife, Nigeria.E-mail: [dokolawole@yahoo.com](mailto:dokolawole@yahoo.com)<sup>3</sup>Department of Pharmaceutics, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria.E-mail: [alamikanra@yahoo.com](mailto:alamikanra@yahoo.com)**Abstract**

This study determined *E. coli* resistance to commonly used antibiotics together with their virulence properties in Ile-Ife, Nigeria. A total of 137 *E. coli* isolates from cases of urinary tract infection were tested for their sensitivity to commonly used antibiotics and possession of virulence factors using standard methods. Their ability to transfer resistance was also determined. The isolates demonstrated a high and widespread resistance (51.1 % to 94.3 %) to all the antibiotics used except Nitrofurantoin (7.3 %). A total of 50 (36.5 %) of the isolates were resistant to 10 of the eleven antibiotics employed. Sixty three per cent (63 %) of the 107 trimethoprim resistant *E. coli* transferred their resistances while amoxicillin, gentamycin, augmentin, tetracycline and erythromycin were co-transferred with trimethoprim. Fifty one (37.2 %) of these multi-resistant isolates possessed one or more virulent factors. The study concluded that urinary tract infection due to *E. coli* in Ile-Ife may be difficult to treat empirically except with nitrofurantoin, due to high resistance to commonly used antibiotics. It is imperative that culture and susceptibility tests be carried out on infecting pathogen prior to treatment, in order to avoid treatment failure and reduce selective pressure that could result in the spread of uropathogenic *E. coli* in the environment.

**Key words:** Urinary tract infection, *Escherichia coli*, antibiotic resistance, virulence factors.

**Introduction**

Urinary tract infections are among the most common bacterial infections in humans and *Escherichia coli* is by far the most commonly recovered bacterial pathogen from both hospital and community patients with this infection (Hryniewicz et al., 2001, Dasgupta et al., 2005). The *E. coli* that cause urinary tract infection are not all the strains from the intestinal tract but a subgroup selected by factors enhancing extra intestinal survival. Such factors include motility by the aid of flagella, structural features such as fimbriae or pili and chemical adhesion (Emody et al., 2003). The type-1 pili also known to be the most widely distributed among uropathogenic *E. coli* binds to mannose containing glycoprotein receptors on facet cells lining the bladder or vaginal epithelial cells and are known to be associated with increased severity of UTI (Venegas et al., 1995; Todar, 2008). An array of other virulence factors has also been identified (Emody et al., 2003) which confer on some faecal *E. coli* the ability to colonise the vaginal mucosa and cause symptomatic urinary diseases. This group of *E. coli* is known collectively as uropathogenic *E. coli* (UPEC) clones (Orskov and Orskov, 1985).

There is the need to eliminate these organisms in order to avoid treatment failure which could lead to proliferation of virulent *E. coli* and consequent morbidity. In settings where resistance to cotrimoxazole (trimethoprim/sulphamethaxole) in *E. coli* is less than 20%, a short course of cotrimoxazole is the recommended empirical treatment for acute uncomplicated cystitis (Lescure et al., 2001). However the ability of *E. coli* to cause urinary tract infections is on the increase, while the ease of treating these infections due to multidrug antibiotic resistance to first line antibiotics such as cotrimoxazole, ampicillin and nitrofurantoin is becoming increasingly elusive. Of greater concern is the recent increase in resistance to fluoroquinolones such as ciprofloxacin and levofloxacin (Hooton, 2003; Karlowsky et al., 2006).

The increasing ability of *E. coli* to cause urinary tract infections and the difficulty encountered in treating these infections due to multidrug antibiotic resistance necessitates updating the knowledge of their drug resistance in a given environment. This is particularly necessary in a suburban community like Ile-Ife of Southwest Nigeria where all kinds of antibiotics are available across the counter with or without prescription (Okeke and Lamikanra, 2001). Hence, the objective of this work was to study and determine the antibiotic susceptibility and resistance of pathogenic *E. coli* isolated from cases of urinary tract infection in Ile-Ife, Nigeria. This is with a view

<http://dx.doi.org/10.4314/ajid.v7i1.1>

to selecting the right antibiotics for effective treatment of urinary tract infections caused by *Escherichia coli*. The study will also demonstrate the virulence factors that contribute to their persistence in UTI patients.

## Materials and Methods

### Isolation of *Escherichia coli*

A total of 137 strains of *E. coli* were isolated from urinary tract infections at two tertiary care hospitals in Ile-Ife between May 2003 and December 2005. Clean voided midstream and suprapubic aspirates urine samples were collected daily with the assistance of hospital medical personnel into sterile universal bottles from both in-patients and out-patients suspected to have a urinary tract infection. Culture was done by the calibrated loop technique delivering approximately 0.01 ml. of urine, and cultured on MacConkey agar (Oxoid, England) or Cystine-Lactose Electrolyte-Deficient (CLED) agar medium to obtain isolated colonies. Only *E.coli* colonies showing a significant growth of  $10^5$  colony forming units per milliliter or more of urine samples after incubation at 37 °C for 24 h were considered in this study.

This was based on colony morphology and cultural characteristics on MacConkey agar and EMB agar. The presence or absence of growth, colour, whether they were mucoid or non-mucoid and consistency of colonies produced by each isolate on the media were observed and recorded. The isolates were further identified using standard microbiological methods (Barrow and Feltham, 1993). All Gram negative isolates that showed positive results for motility, lactose fermentation, indole production, and inability to utilize citrate as a sole carbon source were defined as *E. coli* and stored in Nutrient Agar.

### Antimicrobial susceptibility testing

Isolates were tested for antimicrobial susceptibility by using the standard agar disc diffusion method (NCCLS,1993) on Tryptone soy agar surface already seeded with the organism using cotton tipped applicator (Sterilin Ltd. Middlesex, U.K.). The multidisc used (AB Biodisk) contained the following antibiotics arranged equidistant to each other – amoxicillin, 250 µg; trimethoprim/sulphamethaxole, 25 µg; nitrofurantoin, 300 µg; gentamycin, 10 µg; nalidixic acid, 30 µg; ofloxacin, 30 µg; augmentin, 30 µg; tetracycline, 30 µg; erythromycin, 15 µg; norfloxacin, 10 µg; and ciprofloxacin, 10 µg; The plates were refrigerated at 4 °C for 30 minutes to ensure adequate diffusion of the antibiotics before incubation at 37 °C for 18 h. The diameters of inhibition zones were measured in millimeter, and interpreted in accordance with the manufacturer's recommendations (AB Biodisk; PDM Interpretative Chart).

### Minimum Inhibitory Concentration (MIC) of Trimethoprim

The MIC for all trimethoprim resistant *E. coli* isolates was determined by the agar dilution method (NCCLS,1993). A 1:1000 dilution of overnight culture of each isolate was prepared in sterile distilled water and the resultant suspension was applied to the surface of dried iso sensitest agar containing doubling dilution (1024 – 4mg/l) of trimethoprim lactate (Welcome Foundation, Sweden) in duplicate plates, with a multipoint inoculators. The concentration of trimethoprim inhibiting growth after 24 h incubation at 37 °C was taken as the MIC.

### *In-vitro* Transconjugation experiment

Mating experiment were conducted for all Trimethoprim resistant isolates on Tryptone agar plate with the trimethoprim sensitive, nalidixic acid resistant *E. coli* K-12 C600 as recipient. Transconjugants were harvested on Tryptone Soy Agar plates containing 10 mg/L trimethoprim and 40 mg/L nalidixic acid (Sigma Chemical Company, St. Louis, USA). All transconjugants were screened for threonine marker of *E. coli* K-12 C600 and for resistance to antibiotics to which the donor organisms were resistant.

### Detection of virulence factors

#### Capsule formation

This was done by the combined positive and negative staining method described by Okeke and Lamikanra, [1995]. The organisms appeared red against a blue background, while the presence of capsule was observed as a clear zone around each bacterium.

#### Haemolysin

All the *E. coli* isolates were screened for haemolytic activity on nutrient agar plates containing 7 % washed human erythrocytes. A distinct colony of the organism was streaked and stabbed on the nutrient agar plate containing 7 % washed erythrocyte and incubated at 37 °C for 18 h. The erythrocytes were then observed for lyses, as indicated by the blood free zone surrounding the colony stab.

### Colicin production

This was carried out using the agar overlay method described by Barth et. al. (1978), *E. coli* K-12 C600 was used as indicator organism. Plates were observed for the formation of inhibition zones around the test organism stabs.

### Haemagglutination

Haemagglutination was detected by clumping of erythrocytes by fimbriae of bacteria in the presence of D-mannose using the method described by Evans et al. (1979). Washed erythrocytes were recovered from freshly collected blood from human type 'A' donor. Strains were classified as showing instantaneous haemagglutination (4+); almost instantaneous (within 60 s at room temperature (3+); within 5 min on ice (2+); within 30 min on ice (1+); or no haemagglutination (0).

## Results


A total of 137 *E. coli* strains were isolated from the urine samples that met the inclusion criteria of  $10^5$  colony forming units per millilitre of urine. Those samples without growth or with growth less than  $10^5$  cfu/ml of urine were excluded from this study. Eighty one isolates, representing 59.1% of the total isolates were recovered from female patients, while 56 (40.9%) were isolated from male patients.

### Antibiotic susceptibility studies of *E. coli*


The results showed widespread resistance (51.1 - 91.2 %) of the isolates to all the antibiotics, except nitrofurantoin with resistance rate of 7.3 % (Figure 1). Among the fluoroquinolones, ofloxacin showed the least resistance (51.1 %), followed by Ciprofloxacin (65.7 %) and Norfloxacin (86.9 %). The result also showed (Figure 2) that the *E. coli* isolates were multiply-resistant with the highest percentage of multiresistant isolates skewed toward the highest number of antibiotics. Up to 50 (36.5%) strains were resistant to 10 out of the 11 antibiotics employed. A total number of 20 (14.6 %), 18 (14.14 %) and 13 (9.5 %) isolates were resistant to 7, 8 and 9 antibiotics respectively, while 8 (5.8 %) of the isolates were resistant to all the antibiotics employed.

### Transfer of resistance

Out of the 107 trimethoprim resistant *E. coli* tested, 63.6 % were able to transfer their resistant traits to plasmidless *E. coli* K12 C600. A high percentage of these isolates that transferred their resistances also fall within the highly resistant strains, i.e., those having their MIC above 1000 mg/ml. of trimethoprim. The result also showed that five of the antibiotics: amoxicillin (88.9 %), gentamycin (20 %), augmentin (67.5 %), tetracycline (72.2 %) and erythromycin (57.1 %) were co-transferred with trimethoprim.



**Figure 1:** Percentage resistance of *E. coli* to different antibiotics.



**Figure 2:** Percentage multiresistance of *E. coli* isolates to the antibiotics.

#### Occurrence of *E. coli* with virulence markers

The percentage occurrence of the different virulence markers among the *E. coli* isolates (Table 1) showed that fifty one isolates representing 37.2 % were capsulated. A total of 19 (13.9 %) strains showed mannose resistant haemagglutination, while 13 (9.5 %) produced the exotoxin colicin. Ten (7.3 %) isolates were haemolytic. The four different markers also occurred both singly and in different combinations among the isolates and were all multi-resistant (Table 2).

**Table 1:** Number of Isolates with different Virulence markers

Number (%) of isolates	Virulence property
51 (37.2)	Capsulated
19(13.9)	Mannose resistant haemagglutination
13(9.5)	Colicin
10(7.3)	Haemolysin

#### Discussion

The results of this work showed a higher percentage of isolates from female patients (59.1 %) than males (40.9 %). This is consistent with previous findings that UTI is more common in females than their male counterparts (Foxman et. al., 2000; Aiyegoro et. al., 2007; Omoregie et. al., 2008). There was a wide range of resistance of the *E. coli* isolates [Figure 1] to all the commonly used antibiotics in this environment, namely, amoxicillin, gentamicin, cotrimoxazole, augmentin, ciprofloxacin, norfloxacin, streptomycin and nalidixic acid. The result also showed a higher level of resistance of *E. coli* than were reported by previous workers (Lamikanra and Ndep, 1989). The result is however in agreement with the report that antibiotic resistance in *E. coli* isolates from urinary tract infection is on the increase (Kurutepe et. al., 2005).

The high level of resistance to the fluoroquinolones limits the options for effective treatment of urinary tract infection caused by *E. coli* in this environment. This is because fluoroquinolone antibiotics were considered to be critical antibiotics due to their very high effectiveness against pathogens that are resistant to other antibiotics. It is evident from this study that fluoroquinolones can no longer be employed as alternative to the less effective trimethoprim/sulphamethaxole (Cotrimoxazole) for empirical treatment of UTI caused by *E. coli* within this study area. The only exception among the tested antibiotics is nitrofurantoin, to which the organisms exhibited

<http://dx.doi.org/10.4314/ajid.v7i1.1>

a resistance as low as 7.3 % [Figure 1]. The high sensitivity shown to this antibiotic is consistent with the result of other workers (Gupta et. al., 2001; Karlosky et. al., 2002), in other parts of the world. The reason while nitrofurantoin continues to show high sensitivity is not yet understood, only that this synthetic antibacterial does not belong to the group of any of the other antibiotics. It may also be related to the fact that the drug is not as commonly used as the other anti-infective agents such that, with less consistent drug pressure, the microbial sensitivity is sustained.

**Table 2:** Numbers of uropathogenic *E. coli* isolates with one or more virulence markers and their resistance level.

Virulence Markers	Number of isolates	Resistant to:
<u>One marker</u>		
COL	8	2-10 antibiotics
HL	2	4-10 antibiotics
CAP	22	2-11 antibiotics
MRHA	10	2-11 antibiotics
Total	42	
<u>Two Markers</u>		
COL+HL	2	9-10 antibiotics
HL+CAP	3	9-10 antibiotics
HL+MRHA	0	-
CAP+MRHA	7	6-11 antibiotics
COL+CAP	3	7-10 antibiotics
Total	17	
<u>Three Markers</u>		
HL+CAP+MRHA	1	7 antibiotics
Total	1	

**Key:** COL = Colicin formation, CAP = Capsule, MRHA = Mannose resistant haemagglutination, HL = Haemolysin production.

It is evident from the result of this work that majority of the *E. coli* isolates are highly and multiply-resistant. The reason for this high level of resistance could be due to the fact that ingestion of antibiotics is known to provide selective pressure ultimately leading to a higher prevalence of resistant bacteria (Okeke et. al., 2000). In most towns and cities in Nigeria, these antibiotics are readily made available over the counter without prescriptions. The indiscriminate use and misuse of antibiotics and the consumption of substandard antibiotics as earlier reported (Okeke and Lamikanra, 1995) might have over the years contributed to the high rate of antibiotic resistance recorded in this study.

About 63 % of the trimethoprim resistant isolates were able to transfer their resistance into a plasmidless *E. coli* strain. It is to be noted also that most of these trimethoprim resistant isolates were able to grow in the presence of more than 1000 mg/l of trimethoprim, indicative of high level of resistance. Co-transfer of resistance of trimethoprim and amoxicillin was predominant and this was followed by co-transfer with tetracycline, augmentin erythromycin and gentamycin respectively. Adeleye (1992) reported that while genes encoding multiple antibiotic resistances are not always transferable they are often located on easily mobilised plasmids. Therefore, the widespread antibiotic resistance encountered in these isolates can however, be due not only to the indiscriminate use of drugs in this community, but also to the early transferability of plasmids.

Identification and evaluation of virulence factors are necessary for a more complete understanding of the pathogenesis of *E. coli* UTI and may in turn lead to the logical development of new strategies for the prevention and treatment of UTI and other infections caused by the pathogens. In this study, 37.2 % strains were encapsulated (Table 1) and phenotypic characterisation reveals that eight of these encapsulated strains were mucoid within 18-24 h. Capsules are known to confer serum and phagocyte resistance to some *E. coli* strains (Russo et. al., 1996; Warren, 1997).

Colicin is a narrow spectrum bactericidal macro molecule which is produced by some strains of *E. coli*. Each colicin plasmid is known to confer immunity to the particular colicin which it encodes (Cariksi and Cosar, 2001). Thirteen (9.5%) of the 137 *E. coli* strains in this study produced colicin. Although there have been a dearth of information on colicin production by uropathogenic *E. coli* in this locality, the figure recorded in this study is lower than 25.5 %, 26.2 % and 36.3 % reported in other parts of the world (Cariksi and Cosar, 2001; Davies et. al., 1981; McGeachie, 1965). This difference may be due to reported differences in the characteristics of strains found in different countries during various periods (Djonne, 1985). Okeke et. al. (2000) reported a high rate of colicinogenicity among enteroaggregative *E. coli* (EAEC) strains isolated from children in Southwest Nigeria and suggested (Okeke et. al., 2000) that this may partially explain the documented association of EAEC with persistent diarrhoea (Bhan et. al., 1989; Baqui et. al., 1992) because abundant adherence and elimination of competing commensals may favour prolonged colonisation and treatment failure. This condition may also be applicable in urinary tract infection.

<http://dx.doi.org/10.4314/ajid.v7i1.1>

Agglutination of red blood cells commonly known as haemagglutination is mediated by fimbriae (Dugguid et al., 1979), and is proportionate to the ability to adhere to uroepithelial cells. In mannose resistant haemagglutination (MRHA) the P- blood group antigen acts as a receptor for these organisms and they have improved binding to uroepithelial cells (Emody et al., 2003). In this study 19 (13.9%) of the isolates produced mannose resistant haemagglutination (Table 1). This value is lower than the 30.9 % reported in India (Raksha et al., 2003).

Also, a total of ten (7.3%) of the isolates produced the toxin, haemolysin. The cytolytic protein toxin secreted by most haemolytic *E. coli* isolates is known as alpha-haemolysin. Three (30%) of the ten haemolysin producing *E. coli* were  $\alpha$ -haemolytic. Cytotoxic necrotising factor (CNF-1) production increases the capacity of UPEC strains to resist killing by neutrophils, which in turn permits these bacteria to gain access to deeper tissue and persist better in the lower urinary tract (Rippere-Lampe et al., 2001)

The results also showed that sixty (53.2 %) of the *E. coli* isolates (Table 2) had one or more virulence markers. It has been reported (Raksha et al., 2003) that haemolysin production, presence of capsule and capacity to cause MRHA emerged as important virulence factors in *E. coli* UTI. P-fimbriae which often confers on *E. coli* the capacity to cause MRHA is known to induce higher interleukin (IL) -8, IL-6 and neutrophil responses in the urinary tract (Wullt et al., 2001). In the same way,  $\alpha$ -haemolysin, also known as cytotoxic necrotising factor triggers inflammatory response leading to secretion of IL-6 and chemotoxins which set the pace for pathogenesis of renal disease.

The result of this study revealed the occurrence of some virulence factors namely, haemagglutinin, colicin, haemolysin and capsule, which confer pathogenicity on the predominant *E. coli* isolates from urinary tract infections in this environment. It is now evident that a considerable number of *E. coli* isolates from this study community which, apart from being highly and multiply antibiotic resistant, are well equipped to enter the urinary tract and cause symptomatic disease.

It also showed that empirical treatment of *E. coli* UTI is no longer working in this environment. In order to avoid treatment failure, culture and susceptibility tests should be carried out on infecting pathogens before an antibiotic is selected for treatment. This would discourage the indiscriminate use of antibiotics and reduce selective pressure that could result in the spread of virulent and resistant uropathogenic *E. coli* in the environment.

## References

1. Adeye, A.I. (1992) Conjugal Transferability of Multiple Antibiotic Resistance in three genera of enterobacteriaceae in Nigeria. *J Diarrho Dis Res* 10(2): 93-96
2. Ayegoro, O. A., Igbinosa, O.O., Ogunmwonyi, I. N., Odjadjare, E. E., Igbinosa, O. E. and Okoh A. I. (2007) Incidence of urinary tract infections (UTI) among children and adolescents in Ile-Ife, Nigeria. *Afr J Microbiol Res* 1: 13-19
3. Baqui, A. H., Sack, R. B., Black, R. E., Haider, K., Hossain, A., Alim and Yunus, M., Chowdbury, HR and Sidique, A. K. (1992) Enteropathogens associated with acute and persistent diarrhoea in Bangladeshi children less than 5 years of age. *J. Infect. Dis.* 166, 792 – 796.
4. Barrow, G. and Feltham, R. (1993) *Cowan and Steel Manual for the identification of medical bacteria*. Cambridge University Press; p 331
5. Barth, P. T., Richards, H. and Data, N. (1978) Copy numbers of existing plasmids in *Escherichia coli* K-12. *J Bact*; 135:760-65.
6. Bhan, M. K., Bhandari, N., Sazawai, S., Clemens, J., Raj, P., Levine, M. M., and Kaper, J. B. (1989) Descriptive epidemiology of persistent Diarrhoea among young children in rural northern India. *Bulletin of the World Health Organisation*, 67: 281 – 288.
7. Cariksi, A. I. and Cosar, C. (2001) Colicin production and colicin Typing of uropathogenic *Escherichia coli*. *Turk J Med Sc* 31: 483-85
8. Dasgupta, P., Sacks, S. H., Khan, M. S. and Sheerin, N. S. (2005) Urinary Tract Infections; new insight into a common problem. *Postgrad. Med. J.* 8183-86(Pubmed).
8. Davies, D. L., Falkiner, F. R and Hardy, K. G. (1981) Colicin V production by clinical isolates of *Escherichia coli*. *Infect. Immun.* 31(2), 574 – 579.
10. Djonne, B. K. (1985). Colicin production in relation to pathogenicity factors in strains of *Escherichia coli* isolated from the intestinal tract of piglets. *Acta Med. Scand.* 26: 145.
11. Dugguid, J. P., Clegg, S. and Wilson, M. I. (1979) The fimbrial and Non-fimbrial haemagglutinins of *Escherichia coli*. *J Med Microbiol* 12: 213-28
12. Emody, L., Kerenyi, M. and Nagy, G. (2003) Virulence factors of uropathogenic *Escherichia coli*. *Int. J. Antimicrob Agents* 22:529-33
13. Evans, D. J. Jr., Evans, D. G. and DuPont, H. L., (1979) Haemagglutination patterns of enterotoxigenic and enteropathogenic *Escherichia coli* determined with human, bovine, chicken and guinea pig erythrocytes in the presence and absence of mannose. *Infect Immun* 23: 336-46
14. Foxman, B., Barlow, R. D. Arcy, H., Gillespie, B and, Sobel, J. D. (2000) Urinary tract infection; self-reported incidence and associated costs. *Ann Epidem* 10: 509 – 13.

<http://dx.doi.org/10.4314/ajid.v7i1.1>

15. Gupta, K., Sahm, D. F., Mayfield, D. and Stamm, W. E. (2001) Antimicrobial resistance among uropathogens that cause community – acquired urinary tract infections in women: A nationwide analysis. *Clin Infect Dis* 33: 89-94.
16. Hooton T.M. (2003) Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. *Int. J. Antimicrob Agents* 2: 65-72.
17. Hryniewicz, K., Szczy, K., Sulikowska, A., Jankowski, K., Betlejewska, K. and Hryniewicz W. (2001) Antibiotic Susceptibility of bacterial strains isolated from urinary tract infections in Poland. *J. Antimicrob. Chemother.* 47: 773 - 80.
18. Karlowsky, J. A., Horban, D. J., DeCorby, M. R., Lang, N. M., and Zhanel, G. G. (2006) Fluoroquinolone – Resistant Urinary Isolates of *E. coli* from out patients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance – Quinolone Resistance Study. *Antimicrob. Agents Chemother.* 50(6) 2251 - 2254.
19. Karlowsky, J. A., Kelly, L., Thornsberry, C., Jones, M. E. and Sahm, D. F. (2002). Trends in antimicrobial resistance among urinary tract infection isolates of *Escherichia coli* from female out patients in the United States. *Antimicrob Agent Chemother* 46(8): 2540-45.
20. Kurutepe, S., Surukuoglu, S., Sezgin, C., Gazi, H., Gulay, M. and Ozbakkaloglu, B. (2005) Increasing antimicrobial resistance in *Escherichia coli* isolates from community-acquired urinary tract infections during 1998-2003 in manias Turkey. *Jap J Inf Dis* 58: 159-61.
21. Lamikanra, A. and Ndep, R. B. (1989) Trimethoprim resistance in urinary tract pathogens in two Nigerian hospitals. *J Antimicrob Chemo* 23:151 – 54.
22. Lescure, F. X., Eveillard, M., Douadi, Y. and Eb, F. (2001) Community –acquired multiresistant bacteria : an emerging problem? *J. Hosp. Infect.*; 49: 149 – 151.
23. McGeachie, J. (1965) Bacteriocin typing in urinary infection. *Zbl. Bact., Abt. (Orig.)*, 196, 377 – 384.
24. NCCLS. (1993) Performance standards of antimicrobial disk susceptibility tests, 4th Edn. National Committee for Clinical Laboratory Standards, Villanova, PA, Approved Standard M2 – A5.
25. Okeke, I. N., Fayinka, S.T and Lamikanra, A. (2000) Antibiotic resistance in *Escherichia coli* from Nigerian students, 1986-1998. *Emerg Inf Dis* 6(4): 393-96
26. Okeke IN, Lamikanra A. (1995) Quality and bioavailability of Tetracycline capsules in a Nigerian semi urban community. *Int J Antimicrob Agents* 5: 245-50. multiresistant bacteria : an emerging problem? *J. Hosp. Infect.*; 49: 149 – 151.
27. Okeke, I. N. and Lamikanra, A. (1995) Bacterial capsules; a simple method for demonstration un,der the light microscope. *Brit J Biomed Sc* 52: 321 – 22
28. Okeke, I. and Lamikanra A. (2001) Quality and bioavailability of ampicillin capsules dispensed in a Nigerian semi-urban community *Afr J Med Sc*;30:47-51.
29. Okeke, I. N., Lamikanra, A., Czczulin, Dubovsky, F., Kaper, J. B. and Nataro, J. P. (2000). Heterogenous virulence of Enteroregative *Escherichia coli* strains isolated from children in Southwest Nigeria. *J. Infect. Dis.* 181(1): 252 – 260.
30. Omoregie, R., Erebor, J. O., Ahonkhai, I., Isibor, J. O., Ogefere, H. O. (2008). Observed changes in The prevalence of uropathogens in Benin City, Nigeria *NZ J Med Lab Sci* 62: 29-31 .
31. Orskov and Orskov, (1985). *Escherichia coli* in extra-intestinal infections. *Journal of Hygiene (London)*; 95: 551-575
32. Raksha, R., Srinivasa, H. and Macaden, R. S. (2003) Occurrence and characterization of uropathogenic *Escherichia coli* in urinary tract infections. *Ind. J. Med. Microbiol* 21(2): 102-107
33. Rippere-Lampe, K. E., O'Brien, A. D., Conran, R., and Lock, H. A., (2001) Mutation of the gene encoding cytotoxic necrotizing factor type 1 [cnf(1)] attenuates the virulence of uropathogenic *Escherichia coli*. *Infect Immun* 69(6): 3954 – 3964.
34. Russo, T. A., Brown, J. J., Jodush, S. T. and Johnson, J. R. (1996) The O4 Specific Antigen Moiety of Lipopolysaccharide but not the K54 Group 2 Capsule is important for Urovirulence of an extraintestinal isolate of *Escherichia coli*. *Infect Immun* 2343-48.
35. Todar's Online Textbook of Bacteriology (TOTB): Urinary tract infection. Available on: <http://www.textbookofbacteriology.net/e.coli.htm>
36. Venegas, M. F., Navas, E. L., Gaffney, R. A., Duncan, J. L., Anderson, B. E. and Schaeffer, A. J. (1995) Binding of type 1-piliated *Escherichia coli* to vaginal mucus. *Infect and Immun* 63(2): 416-22.
37. Warren, J. W. (1997) Host parasite interactions and host defence mechanisms...Eds (Little Brown, London). 873-894.
38. Wullt, B., Bergsten, G., Connell, H., Rollano, P., Gebratsedik, N., Hang, L. and Svanborg, C. (2001) P-fimbriae trigger mucosal responses to *Escherichia coli* in the human urinary tract. *Cell Microbiol* 3(4): 255-264.